Over 150 Total Lots Up For Auction at One Location - CA 05/31

Cardio Diagnostics Holdings, Inc. expands HeartRisk platform offering to diverse markets in conjunction with nationwide rollout

Press releases may be edited for formatting or style | February 15, 2024 Artificial Intelligence Cardiology

Impact on Healthcare Costs and Chronic Disease Management

The expansion of the HeartRiskā„¢ platform is aligned with the broader trend in healthcare towards prevention and value-based care. Preventive measures are not only lifesaving but also economically beneficial, with an estimated return of $6.30 in savings for every $1 invested. Active strategies for risk factor reduction, prevention, and treatment of CVD, powered by precision population analytics, are key to addressing these growing cardiovascular cost challenges.


About Cardio Diagnostics
Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The Company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine ("Core Technology") for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease.

Back to HCB News

You Must Be Logged In To Post A Comment